[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ototoxic-hearing-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ototoxic-hearing-loss":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100587521","cisplatin-induced-cochlear-and-vestibular-damage-in-head-and-neck-cancer-100587521",false,"NCT06929468","Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer","Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Squamous Cell Carcinoma: A Cohort Study","Inclusion Criteria:\n\n* Diagnosis of head and neck squamous cell carcinoma\n* Cisplatin-based chemoradiotherapy (monotherapy or combination-therapy, adjuvant or neo-adjuvant) or only radiotherapy (control group)\n* Age 18 to 85 years\n* Signed agreement and willingness to participate in the study and adhere to the study protocol\n\nExclusion Criteria:\n\n* Severe hearing impairment (WHO grade 3 or 4, corresponding to an audiometric ISO value of ≥61 dB in the better ear at frequencies of 500, 1000, 2000 and 4000 Hz)\n* Self-reported tinnitus or vestibular dysfunction in the last 3 months (only lead to exclusion of the corresponding secondary objectives, not to complete exclusion from the study)\n* Current cochlear implant\n* Concurrent treatment with loop diuretics (e.g. furosemide), aminoglycoside antibiotics or other known ototoxic substances in the last three months\n* Acute psychosis or serious psychiatric illness\n* Addiction disorder","ALL","18 Years","85 Years",{"count":20,"type":21},55,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.",[26,27,28,29,30,31,32,33,34,35,36],"Ototoxic Hearing Loss","Ototoxicity, Drug-Induced","Cisplatin-induced Hearing Loss","Cisplatin Ototoxicity","Head and Neck Cancer","Dizzyness","Inner Ear Hearing Loss","Vestibular Disease","Squamous Cell Carcinoma of the Head and Neck","Deafness","Hearing Loss","NOT_YET_RECRUITING","2025-04-14",{"date":40,"type":41},"2025-04-16","ACTUAL",{"date":43,"type":21},"2025-07",{"date":45,"type":21},"2027-06",{"name":47,"class":48},"Simon Jäger","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100584136","ototoxicity-in-patients-with-mom-hip-bearings-100584136","NCT06885411","Ototoxicity in Patients With MoM Hip Bearings","Ototixicity in Patients With a Metal-on-Metal Hip Arthroplasty","GODMOTHER","Inclusion Criteria:\n\n* all MoM patients from the different clinics\n* revision MoM\n* willing to participate\n* speak\u002Fwrite the Dutch language\n\nExclusion Criteria:\n\n* Not willing to participate\n* previous ENT surgery or ENT pathology",true,{"count":60,"type":21},200,"1 Day","The goal of this observational study is to learn about ototoxicity in patients with a MoM hip arthroplasty. The main question it aims to answer is:\n\n• What is the prevalence of hearing loss in patients with high and low plasma metal concentrations.",[26,64,65,66],"Cobalt Poisoning","Chromium Causing Toxic Effect","Arthroplasty Complications",[68],"Metal-on-Metal implant; Cobalt; Chromium; Hip arthroplasty; auditory system; Otoxicity","RECRUITING","2025-03-17",{"date":72,"type":41},"2025-03-20",{"date":74,"type":41},"2023-02-01",{"date":76,"type":21},"2025-12-01",{"name":78,"class":48},"Reinier Haga Orthopedisch Centrum",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":49},"100449228","phase-2-efficacy-of-sodium-thiosulfate-and-mannitol-in-reducing-ototoxicity-in-adult-patients-receiving-cisplatin-chemotherapy-100449228","NCT05129748","Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy","A Multicenter Randomized Phase II Clinical Trial of the Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy","Inclusion Criteria:\n\n* Patients undertaking systemic cisplatin therapy as part of their cancer treatment\n* Age ≥ 18\n* Willing to provide informed consent\n* ECOG performance status 0-2\n* For female of child-bearing potential, a negative pregnancy test (beta-HCG) prior to study treatment is required\n* Any patient who is of reproductive age should provide written agreement to use adequate contraception for the duration of the trial\n\nExclusion Criteria:\n\n* Age less than 18\n* Preexisting severe to profound sensorineural hearing loss (unilateral or bilateral) (speech reception threshold \\>70dB, or word recognition score \\\u003C50%) as confirmed with an audiogram\n* History of Meniere's or fluctuating hearing loss\n* Asymmetrical hearing loss (bone conduction threshold difference of: (a) 20 dB threshold difference at a single frequency, (b) 15 dB threshold difference at 2 frequencies, (c) 10 dB threshold difference at 3 frequencies\n* Abnormal renal function (creatinine clearance \\\u003C60 ml\u002Fmin)\n* Abnormal liver function (liver function tests (ALT and ALP) \\>2.5 times upper limit of normal without liver metastasis and \\>5 times upper limit of normal with liver metastasis\n* Previous hypersensitivity to STS or mannitol\n* Pregnant and\u002For nursing women\n* Patient unable to follow the protocol for any reason",{"count":87,"type":21},92,"INTERVENTIONAL",[90],"PHASE2","One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss. Specifically, sodium thiosulfate has been found to protect the cells in the inner ear, and may therefore prevent hearing loss. Mannitol can help sodium thiosulfate enter the inner ear, and ponteially increase the effectiveness of sodium thiosulfate. This study aims to assess the efficacy of sodium thiosulfate and mannitol to reduce the hearing impairment caused by cisplatin chemotherapy.",[26],[36,35,94,95,96,97],"Cisplatin-induced Ototoxicity","Sensorineural hearing loss","Ear diseases","Sodium Thiosulfate","2023-04-12",{"date":100,"type":41},"2023-04-14",{"date":102,"type":41},"2023-02-15",{"date":104,"type":21},"2027-12",{"name":106,"class":48},"Sunnybrook Health Sciences Centre"]